Company: AZN
Filing Date: 2025-11-06
Form Type: 6-K
Source: 0001654954-25-012630
Chunk: 0

Company: ASTRAZENECA PLC
Filing Date: 2025-11-06
Form: 6-K
Chunk 0
---
#### FORM 6-K
<div align='center'>SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

For the month of November 2025

Commission File Number: 001-11960</div>

#### AstraZeneca PLC
<div align='center'>1 Francis Crick Avenue

Cambridge Biomedical Campus

Cambridge CB2 0AA

United Kingdom

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F X Form 40-F __

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes __ No X

If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____________</div>

#### AstraZeneca PLC
<div align='center'>INDEX TO EXHIBITS</div>

#### 1.

#### 9M and Q3 2025 results
**6 November 2025

AstraZeneca results: 9M and Q3 2025

Continued strong commercial performance and unprecedented pipeline delivery in the year to date

Revenue and EPS summary**

|                       | 9M 2025 | % Change |      | Q3 2025 | % Change |     |
|                       |      $m |   Actual | CER1 |      $m |   Actual | CER |
| -                     
 Product Sales         |  41,035 |        9 |    9 |  14,365 |       11 |   9 |
| - Alliance Revenue    |   2,108 |       41 |   41 |     815 |       46 |  44 |
| Product Revenue